Degrees and Certifications:
Chief Financial Officer
Keith is the Chief Financial Officer of Fibrocell, a publicly-traded autologous cell & gene therapy company focused on rare diseases of the skin and connective tissue. Prior to Fibrocell, Keith served as Senior Vice President and Chief Financial Officer of NuPathe, a specialty pharmaceutical company that was acquired by Teva Pharmaceuticals. Prior to joining NuPathe, Keith was the Chief Financial Officer and a member of the board of directors of PuriCore plc, a medical technology company listed on the London Stock Exchange. Prior to that, he served as Vice President and Chief Financial Officer of Biosyn and in a variety of roles with ViroPharma, Century Capital Associates (a healthcare-focused consulting firm), and the Healthcare & Life Sciences Practice of KPMG. Keith earned a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from The Wharton School at the University of Pennsylvania.